EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A TGF-βR/IL-2R immunomodulatory fusion protein transforms immunosuppression into T cell activation to enhance adoptive T cell therapy

Yapeng Su iD, Ashley Thelen, Lena V Wirth, Cody M Jenkins, Sam R Mak, Daniel G Chen, Raphael Gottardo, Philip D Greenberg iD

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2516951122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Yapeng Su und 7 weiteren Autor:innen. Beteiligte Einrichtung: Program in Immunology, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Lymphocyte Activation, Receptors, Transforming Growth Factor beta, Recombinant Fusion Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIH HHS, Hartwell Foundation (HARTWELL).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive T cell therapies have shown limited efficacy against solid tumors due in part to immunosuppressive cues such as from TGF-β and insufficient survival/proliferative signals within the tumor microenvironment (TME). We engineered chimeric immunomodulatory fusion proteins (IFPs) that convert immunosuppressive TGF-β signals into proliferative/survival Interleukin 2 (IL-2) signals in T cells. Chimeric TGF-βR/IL-2R IFPs were constructed by fusing extracellular domains of the TGF-β receptor chains with intracellular domains of IL-2Rβ and IL-2Rγ to enable TGF-β binding to trigger STAT5 phosphorylation and activate the downstream IL-2 pathway. In human primary CD8 + T cells, select IFP designs robustly induced p-STAT5 upon exposure to TGF-β1, and simultaneously reduced canonical SMAD2/3 signaling. IFP-expressing T cells proliferated and displayed enhanced viability in response to TGF-β1, effectively leveraging TGF-β-rich conditions to outcompete nontransduced cells. Transcriptomic analyses revealed that IFP signaling promoted T cell activation and allowed maintenance of stemness during culture with TGF-β. Functionally, coexpressing IFPs with a mesothelin-specific T cell receptor improved tumor killing and promoted T cell expansion in the presence of TGF-β1, highlighting both neutralization of TGF-β–mediated suppression and enhanced proliferation. TGF-βR/IL-2R IFPs appear promising for reprogramming the signals T cells receive in the TME and improving efficacy of adoptive T cell therapy in solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveLymphocyte ActivationReceptors, Transforming Growth Factor betaRecombinant Fusion ProteinsReceptors, Interleukin-2HumansInterleukin-2Signal TransductionSTAT5 Transcription FactorCD8-Positive T-LymphocytesTumor MicroenvironmentPhosphorylationTransforming Growth Factor betaImmunosuppression TherapyT-Lymphocytes

Stichwörter der Autor:innen

T cell engineeringT cell receptor (TCR) T cell therapyadoptive T cell therapycancer immunotherapy

Substanzen

Receptors, Transforming Growth Factor betaRecombinant Fusion ProteinsInterleukin-2STAT5 Transcription FactorReceptors, Interleukin-2Transforming Growth Factor beta

Autor:innen und Institutionen

  • Program in Immunology, Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109.
  • Herbold Computational Biology Program, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109.
  • Department of Cellular Genetics, Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton CB10 1SA, United Kingdom.
  • Cambridge Stem Cell Institute, Cambridge Biomedical Campus, University of Cambridge, Cambridge CB2 0AW, United Kingdom.
  • Division of Clinical Research and Innovation, Biomedical Data Science Centre, Lausanne University Hospital and University of Lausanne, Lausanne CH-1005, Switzerland.
  • Department of Immunology, University of Washington, Seattle, WA 98109.

ORCID-Profile: Yapeng Su, Philip D Greenberg

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Hartwell Foundation (HARTWELL)
  • Damon Runyon Cancer Research Foundation (DRCRF)
  • NIH

Zitieren

APA

Su, Y., Thelen, A., Wirth, L. V., Jenkins, C. M., Mak, S. R., Chen, D. G., Gottardo, R., & Greenberg, P. D. (2025). A TGF-βR/IL-2R immunomodulatory fusion protein transforms immunosuppression into T cell activation to enhance adoptive T cell therapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2516951122

Vancouver

Su Y, Thelen A, Wirth LV, Jenkins CM, Mak SR, Chen DG, et al. A TGF-βR/IL-2R immunomodulatory fusion protein transforms immunosuppression into T cell activation to enhance adoptive T cell therapy. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2516951122

BibTeX
@article{Su2025,
  author = {Su, Yapeng and Thelen, Ashley and Wirth, Lena V and Jenkins, Cody M and Mak, Sam R and Chen, Daniel G and Gottardo, Raphael and Greenberg, Philip D},
  title = {A TGF-βR/IL-2R immunomodulatory fusion protein transforms immunosuppression into T cell activation to enhance adoptive T cell therapy},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2516951122}
}
Kostenlos starten →